Expect to grow 25-28% in FY12: Panacea Biotec

2219 Investors following Panacea Biotec. Share this News with them.

0

Like this story, share it with millions of investors on M3

Expect to grow 25-28% in FY12: Panacea Biotec

In an interview with CNBC-TV18, Rajesh Jain, Joint MD, Panacea Biotec says, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) margins have grown considerably in Q4. He expects company to grow 25-28% in FY12.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Midcap Radar on CNBC-TV18 Watch the full show » ALSO READ See latest News about Panacea Biotec See previous management interviews See what other Experts & Brokerages are saying about Panacea Biotec Panacea Biotec BSE | NSE 30/05/12 Are Mutual Funds betting on Panacea Biotec?

Panacea Biotec has announced its fourth quarter results. The company's Q4 net profit was down 25% at Rs 43 crore versus Rs 57.5 crore. Its net sales were up 9% at Rs 340 crore versus Rs 313 crore.

In an interview with CNBC-TV18, Rajesh Jain, Joint MD, Panacea Biotec says, the company's earnings before interest, taxes, depreciation, and amortization (EBITDA) margins have grown considerably in Q4.

He expects company to grow 25-28% in FY12.

Also read: Panacea Biotec Q4 net profit down 25% at Rs 43cr

Below is the verbatim transcript of his interview with Gautam Broker and Ekta Batra of CNBC-TV18. Also watch the accompanying video.

Q: Your profit has fallen to Rs 43 crore versus Rs 57.5 crore as compared to the year earlier. What is the reason for this decline?

A: Our earnings before interest, taxes, depreciation, and amortization (EBITDA) margins have grown considerably in Q4. Last year, we have had some income coming out of the foreign exchange earning which was reflected in last quarter. It was basically an accounting treatment because of which our profit for the last quarter, last financial year were very highly rated. But when you look at the EBITDA margins, the company has grown even in Q4 this year as compared to the Q4 last year.

Q: In FY12, what is the kind of growth rate formulations business would have and also your vaccine segment?

A: On an average, the whole company has been growing close to 28-27% or 25% every year. I think that's the kind of mood we do expect that even in 11-12 we will continue. In the pharmaceutical sector, we have had, on an average, the total growth of around 24%, which we believe is something that we can even look at even in '11-12.

When it comes to the vaccines' business, I think we are noticing that the three year contract, this will be the second year running for easy five and we will be able to maintain our projections as you have seen for the pervious years in the vaccine business segment also.